Pfizer Inc. (NYSE: PFE) announced the implementation of its hemophilia therapy Hympavzi (marstacimab) in China’s Boao Lecheng Medical Tourism Pilot Zone. The drug, approved in the U.S. and European Union, is the first innovative therapy to be administered subcutaneously once weekly via a pre-filled injection pen for hemophilia A and B.
Drug Profile
Marstacimab is a tissue factor pathway inhibitor (TFPI) targeting the Kunitz 2 domain of TFPI, a natural anticoagulation protein. The drug prevents blood clot formation and was approved in the U.S. and EU for hemophilia A and B.
Regulatory Timeline
- August 2023: Hympavzi filed as a Category 1 biologic drug in China.
- October 2023: Included in China’s Care Plan program for rare disease drug development.-Fineline Info & Tech
Leave a Reply